Home/Clinical Trials
RecruitingPhase 2CT-2026-121
Gene therapy CLV-508 in ambulatory boys with Duchenne
Duchenne muscular dystrophy · Rare Disease
Ages 4 to 17 years230 participantsSydney, Australia, Houston, TX
RecruitingPhase 3CT-2026-101
Emzaratinib after surgery in early-stage lung cancer
Non-small cell lung cancer · Oncology
Ages 18 years and older740 participantsChicago, IL, London, UK +2 more
RecruitingPhase 3CT-2023-112
Subcutaneous trelanemab in early Alzheimer's disease
Alzheimer's disease · Neuroscience
Ages 50 to 85 years950 participantsChicago, IL, Berlin, Germany
RecruitingPhase 2CT-2025-114
CLV-318 in treatment-resistant depression
Depression · Neuroscience
Ages 18 to 80 years230 participantsHouston, TX, Sydney, Australia +1 more
RecruitingPhase 1CT-2025-122
CLV-515 in adults with Fabry disease
Fabry disease · Rare Disease
Ages 18 years and older80 participantsSeoul, South Korea, San Diego, CA +2 more
RecruitingPhase 3CT-2024-111
Solekizumab in children with plaque psoriasis
Plaque psoriasis · Immunology
Ages 4 to 17 years1,230 participantsBerlin, Germany, Boston, MA
RecruitingPhase 3CT-2023-116
Once-weekly lorvatide in adults with obesity
Obesity · Cardiometabolic
Ages 18 years and older730 participantsBoston, MA, San Diego, CA +3 more
RecruitingPhase 3CT-2026-105
Tazulimab-cvra in newly diagnosed multiple myeloma
Multiple myeloma · Oncology
Ages 18 years and older1,120 participantsToronto, Canada, Raleigh, NC +1 more
RecruitingPhase 2CT-2023-108
CLV-226 in adolescents and adults with atopic dermatitis
Atopic dermatitis · Immunology
Ages 12 years and older370 participantsBerlin, Germany, London, UK +1 more
RecruitingPhase 2CT-2025-102
Bispecific CLV-140 in extensive-stage small cell lung cancer
Small cell lung cancer · Oncology
Ages 18 years and older290 participantsLondon, UK, Sydney, Australia
RecruitingPhase 1CT-2026-109
CAR-T cell therapy CLV-233 in refractory lupus
Systemic lupus erythematosus · Immunology
Ages 18 to 80 years50 participantsTokyo, Japan, Berlin, Germany +2 more
RecruitingPhase 2CT-2025-118
CLV-419 in heart failure with preserved ejection fraction
Heart failure · Cardiometabolic
Ages 18 to 75 years270 participantsToronto, Canada, Tokyo, Japan +2 more
Study listings are fictional. Talk with your doctor before joining any clinical trial.